Published 29, March 2020,
CML, TKI treatment and COVID-19 disease
Authors: Dr Delphine Rea, Saint-Louis University Hospital, Paris, France and Professor Rudiger Hehlmann, ELN/EHA-SWG for CML
Prophylactic interruption of TKI is not recommended as it may lead to loss of response and CML relapse/progression, especially if access to regular monitoring of CBC counts and BCR-ABL transcripts is altered by the epidemic context. In patients facing resistance or intolerance to current TKI, it is not recommended to delay a change in therapy as outcome may be jeopardized.